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Abstract
The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase
positioned at a central point in a variety of cellular signaling cascades. The established involvement
of mTOR activity in the cellular processes that contribute to the development and progression of
cancer has identified mTOR as a major link in tumorigenesis. Consequently, inhibitors of mTOR,
including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed
and assessed for their safety and efficacy in patients with cancer. Temsirolimus is an intravenously
administered agent approved by the US Food and Drug Administration (FDA) and the European
Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC). Everolimus
is an oral agent that has recently obtained US FDA and EMEA approval for the treatment of
advanced RCC after failure of treatment with sunitinib or sorafenib. Ridaforolimus is not yet
approved for any indication. The use of mTOR inhibitors, either alone or in combination with other
anticancer agents, has the potential to provide anticancer activity in numerous tumor types. Cancer
types in which these agents are under evaluation include neuroendocrine tumors, breast cancer,
leukemia, lymphoma, hepatocellular carcinoma, gastric cancer, pancreatic cancer, sarcoma,
endometrial cancer, and non-small-cell lung cancer. The results of ongoing clinical trials with mTOR
inhibitors, as single agents and in combination regimens, will better define their activity in cancer.
Introduction
The mammalian target of rapamycin (mTOR) is a serine/
threonine kinase that is ubiquitously expressed in mam-
malian cells [1]. Through its downstream effectors, 4EBP1
and P70S6 kinase (S6K), mTOR is involved in the initia-
tion of ribosomal translation of mRNA into proteins nec-
essary for cell growth, cell cycle progression, and cell
metabolism [1]. mTOR senses and integrates signals initi-
ated by nutrient intake, growth factors, and other cellular
stimuli to regulate downstream signaling and protein syn-
thesis. This regulation can prevent cells from responding
to growth and proliferation signals when the supply of
nutrients and energy within the cell is insufficient to sup-
port these cellular processes and can allow cells to
respond to these signals when nutrients and energy are
abundant [2]. Inappropriate mTOR activation has been
implicated in the pathogenesis of numerous tumor types
[3,4]. This article will describe the normal functions of
mTOR, its dysregulation in cancer, and its value as a target
for inhibition by anticancer agents.
mTOR Structure and Function
mTOR is a key protein evolutionarily conserved from
yeast to man; embryonic mutations in mTOR are lethal
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[3]. Two mTOR complexes participate in 2 functionally
disparate protein complexes, mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2). mTORC1
is associated with the activity that correlates with the cel-
lular endpoints observed through the inhibitory effects of
rapamycin. Rapamycin was known almost 20 years before
its substrate, a large (250 kDa) protein, designated "target
of rapamycin" (TOR), was identified. The mammalian
orthologue is termed "mammalian target of rapamycin"
[5]. mTORC2 is not responsive to rapamycin, and while
this mTOR complex is not well defined, its function
appears to be involved in cytoskeletal dynamics. For the
purposes of this article, we will discuss only mTORC1 and
refer to it as mTOR.
In normal cells, positive and negative regulators upstream
of mTOR control its activity (Figure 1) [3]. Positive regu-
lators include growth factors and their receptors, such as
insulin-like growth factor-1 (IGF-1) and its cognate recep-
tor IFGR-1, members of the human epidermal growth fac-
tor receptor (HER) family and associated ligands, and
vascular endothelial growth factor receptors (VEGFRs)
and their ligands, which transmit signals to mTOR
through the PI3K-Akt and Ras-Raf pathways. Negative reg-
ulators of mTOR activity include phosphatase and tensin
homolog (PTEN), which inhibits signaling through the
PI3K-Akt pathway, and tuberous sclerosis complex (TSC)
1 (hamartin) and TSC2 (tuberin). Phosphorylation of
TSC2 by Akt releases its inhibitory effect on mTOR and
upregulates mTOR activity. Another negative regulator,
LKB1, is in an energy-sensing pathway upstream of TSC
[6].
mTOR signals through its downstream effectors, 4EBP1
and S6K, to initiate ribosomal translation of mRNA into
protein. mTOR activation leads to increased synthesis of
multiple proteins, including several that have been impli-
cated in the pathogenesis of multiple tumor types. Exam-
ples include cyclin D1, which is instrumental in allowing
progression of cells through the cell cycle [7], hypoxia-
inducible factors (HIFs), which drive the expression of
angiogenic growth factors (eg, vascular endothelial
growth factor [VEGF], platelet-derived growth factor-β
[PDGFβ ]) [1], and certain proteins involved in nutrient
transport [8].
mTOR Is Implicated in the Development and Progression 
of Various Tumor Types
The PI3K-Akt pathway is an important regulator of cell
growth and survival [9]. In many tumors, components of
this pathway are dysregulated (Table 1), permitting unre-
stricted cancer cell growth and proliferation and evasion
of apoptosis, contributing to tumorigenesis [3,4].
Increased mTOR activity appears to be promoted by dys-
regulation of the regulators of mTOR, in particular, the
PI3K/Akt/mTOR pathway.
mTOR signaling is critical in the development of many
tumors, including renal cell carcinoma (RCC), in which
mTOR can play a specific role in the angiogenesis path-
ways that are frequently up-regulated [10]. The pathobiol-
ogy of RCC, and tumors with clear cell histology in
particular, involves mutation or loss of expression of the
von Hippel-Lindau (VHL) gene. In about 75% of clear cell
RCC cases, the function of the VHL protein is lost. VHL is
a ubiquitin ligase that targets HIF-1α for proteasomal deg-
radation, and its loss results in the accumulation of HIF
[11]. mTOR regulates the synthesis of HIF-1α, and when
loss of VHL function coincides with upregulation of
mTOR activity, this scenario can drive overexpression of
angiogenic growth factors, including VEGF and PDGFβ
[11]. Proteins in the PI3K/Akt/mTOR pathway that are
dysregulated in cancer, such as PTEN, IGF-1/IGF-1R, and
TSC, also contribute to RCC tumorigenesis (Table 2).
Hereditary loss of TSC is associated with an increased inci-
dence of several tumor types, including kidney tumors
[12].
This defined role for mTOR activity in the cellular proc-
esses that contribute to the development and progression
of multiple tumor types has established mTOR as a major
link in tumorigenesis. Preclinical data have supported the
pivotal role of mTOR in cancer and led to the develop-
ment of mTOR inhibitors as a therapeutic target [13].
The Development of mTOR Inhibitors
Rapamycin (sirolimus), an antifungal agent with immu-
nosuppressive properties, was isolated in 1975 on the
island of Rapa Nui [14]. In the 1990s, the substrate for
rapamycin was identified as TOR, the mammalian ana-
logue is designated mTOR [4]. Rapamycin was analyzed
for anticancer activity against a panel of human cancer cell
lines by the US National Cancer Institute in the 1980s and
was found to have broad anticancer activity [15]. How-
ever, clinical development of mTOR inhibitors as antican-
cer agents was less than successful at that time due to
unfavorable pharmacokinetic properties [13]. In the
interim, sirolimus (Rapamune, Wyeth Pharmaceuticals)
has been used in combination with corticosteroids and
cyclosporine as a preventive therapy for kidney transplant
rejection in the United States and Europe [16]. Addition-
ally, an orally available rapamycin analogue, everolimus,
is approved for use as a preventive therapy for transplant
rejection in renal and cardiac transplantation patients in
Europe [17-19].
The revival of mTOR inhibitor evaluation as anticancer
agents began with rapamycin analogues that have a more
favorable pharmacokinetic profile than the parent mole-Journal of Hematology & Oncology 2009, 2:45 http://www.jhoonline.org/content/2/1/45
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cule. Currently, those analogues include temsirolimus
(CCI-779, Torisel, Wyeth Pharmaceuticals), everolimus
(RAD001, Afinitor, Novartis Pharmaceuticals), and rida-
forolimus (AP23573; formerly deforolimus, ARIAD Phar-
maceuticals). The chemical structures of these
compounds are shown in Figure 2. These agents have a
similar mechanism of action, though they have disparate
pharmacokinetic properties.
These drugs are small molecule inhibitors that function
intracellularly, forming a complex with the FK506 bind-
ing protein-12 (FKBP-12), which is then recognized by
mTOR. The resultant complex prevents mTOR activity [4].
These inhibitors are similar to rapamycin in that they
affect only mTORC1, but not mTORC2. The function of
mTORC2 and its role in normal and cancerous cells
remains relatively undefined. mTOR inhibition results in
the abrogation of a number of cellular endpoints impli-
cated in tumorigenesis. Many of the key acquired capabil-
ities of cancer cells can be affected by the inhibition of
dysregulated mTOR activity, including cell cycle progres-
sion, cellular metabolism, cellular survival, and angiogen-
esis [3,13].
Differences among the mTOR inhibitors include metabo-
lism, formulation, and schedule of administration. Tem-
sirolimus is a pro-drug, and its primary active metabolite
is rapamycin (sirolimus) [20]. Temsirolimus is approved
by the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMEA) for the treatment of
advanced RCC. It is administered intravenously on a
once-weekly schedule. It is supplied in vials that must be
refrigerated and protected from light, and it must be
diluted twice before administration [21]. Ridaforolimus is
not a pro-drug [22], but like temsirolimus, it is also
administered intravenously on an intermittent schedule,
although an oral formulation is currently being evaluated
in sarcoma [23,24]. Everolimus is an orally available
mTOR inhibitor that is typically administered on a con-
tinuous daily schedule. Everolimus is also being adminis-
tered in clinical trials on a weekly schedule, but the
continuous, daily dosing schedule appears to be optimal
for certain tumor types [25]. Weekly administration is
being investigated in combination regimens. Everolimus
has recently obtained US FDA and EMEA approval for the
treatment of advanced RCC after failure of treatment with
sunitinib or sorafenib.
Phase I Studies and Safety of mTOR Inhibitors
The phase I dose-finding studies for temsirolimus and
ridaforolimus were conventional in design, in that they
attempted to establish a maximum tolerated dose through
dose escalation [22,26,27]. In contrast, the everolimus
studies relied on pharmacokinetic and pharmacodynamic
modeling, as well as traditional dose-escalation method-
ology, to provide for rational selection of the optimal
doses and schedules for exploration in future clinical trials
[25,28,29]. Data from these studies showed that mTOR
inhibition with everolimus was dose dependent and that
continuous daily dosing produced more profound mTOR
inhibition than weekly dosing, [25,28,29] and everolimus
had acceptable tolerability at the highest dosages studied
[25,29]. The results of phase I studies conducted with
ridaforolimus, everolimus, and temsirolimus are summa-
rized in Table 3[22,25,26,29].
Phase I safety analyses showed that the mTOR inhibitors
are generally well tolerated. Class-specific adverse events
(AEs) are consistently observed with each of the 3 agents,
most commonly including mild to moderate stomatitis/
oral mucositis, skin rash/erythema, and metabolic abnor-
malities (hyperglycemia and hyperlipidemia)
[22,25,26,29]. Noninfectious pneumonitis also appears
to be a class effect of mTOR inhibitors and has been
reported with everolimus and temsirolimus [25,30,31].
Temsirolimus has been associated with infusion reac-
tions, and the administration protocol was altered to
include diphenhydramine pretreatment before tem-
sirolimus infusion in subsequent studies [20].
Positive and negative regulators of mTOR activity Figure 1
Positive and negative regulators of mTOR activity. 
Proteins that activate mTOR are shown in green, and those 
that suppress mTOR activity are shown in red.
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The pivotal role that mTOR plays in cellular signaling sug-
gests a broad range of clinical utility, and indeed, phase I
clinical evaluations of all 3 mTOR inhibitors provided
preliminary evidence of anticancer activity in multiple
tumor types. Activity in RCC was seen with each agent.
Clinical programs for each of these agents continue to
develop in multiple tumor types.
mTOR Inhibitors in Renal Cell Carcinoma
Temsirolimus
Based on phase I activity in RCC, a phase II temsirolimus
study was conducted in 111 heavily pretreated patients
with advanced RCC of all risk categories [31]. Tem-
sirolimus was administered intravenously once weekly at
fixed doses of 25 mg, 75 mg, or 250 mg. This study sup-
ported the activity of temsirolimus seen in phase I trials.
One complete response (CR), 7 partial responses (PRs),
and 29 minor responses were observed. Dose level did not
appear to influence response, but more dose reductions
and discontinuations were observed at the higher dose
levels, suggesting that the 25-mg dose should be used for
future studies. In addition, 5 patients treated with tem-
sirolimus 75 mg developed pneumonitis. Retrospective
classification of patients into good, intermediate, and
Table 1: Components of the PI3K/Akt/mTOR Pathway Frequently Deregulated in Cancer
Target Type of Protein Genetic Aberration Tumor Types
EGFR [88] Tyrosine kinase receptor Amplification, mutation Colorectal, lung, gastric, pancreas, liver, lung, others
HER2 [89] Tyrosine kinase receptor Expression Breast
ER [90] Hormone receptor Expression Breast, endometrial
PTEN [91] Lipid phosphatase Silencing, allele loss Glioma, endometrial, prostate, melanoma, breast
PI3KCA [92] Serine-threonine kinase Mutations Colorectal, breast, lung, brain
TSC1 [93] TSC complex protein Mutation Bladder
LKB1 [94,95] Serine-threonine kinase Mutation, silencing Colorectal, lung
K-ras [96] GTP-binding kinase Mutation Colorectal, pancreas, lung, melanoma
BCR-ABL [97] Tyrosine kinase Translocation CML, ALL
VHL [98] Ubiquitin ligase Loss of heterozygosity, mutation, silencing Kidney, hemangioblastomas
Table 2: Components of the PI3K-Akt-mTOR Pathway Deregulated in RCC
Target Type of Protein Genetic Aberration Potential Relevance in RCC
IGF-1, IGF-1R [99] Growth factor, tyrosine kinase receptor Overexpression Patients with IGF-1R+ clear cell RCC 
(ccRCC) have shorter survival than 
those with IGF-1R-negative ccRCC 
[100]
PTEN [91] Lipid phosphatase Silencing, allele loss PTEN expression may be lost early in 
RCC carcinogenesis [101]
PTEN-deficient tumor cells have 
increased sensitivity to mTOR inhibition 
[102]
TSC1/TSC2 [12] TSC complex protein Hereditary loss Hereditary loss leads to an increased 
incidence of several tumor types, 
including kidney tumors [12].
The TSC tumor suppressors are key 
components in the upstream regulation 
of mTOR [103].
VHL [98] Ubiquitin ligase Loss of heterozygosity, mutation, 
silencing
Up to 75% of clear cell RCCs have lost 
the function of the von Hippel-Lindau 
(VHL) gene [11], resulting in 
accumulation of HIF-1α, a protein that 
controls the expression of genes 
involved in angiogenesis.Journal of Hematology & Oncology 2009, 2:45 http://www.jhoonline.org/content/2/1/45
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poor risk groups similar to the Memorial Sloan-Kettering
Cancer Center (MSKCC) prognostic risk criteria for previ-
ously untreated patients [32] suggested that temsirolimus
was more effective in patients with intermediate and poor
risk than in those with favorable risk [31].
Based on these results, a phase III double-blind rand-
omized trial compared temsirolimus, interferon-α (IFN-
α), and temsirolimus + IFN-α in 626 poor-risk (≥3 of 6
prognostic risk factors) patients with previously untreated
RCC [33]. Temsirolimus was administered at a dose of 25
mg weekly. Compared with IFN-α alone, temsirolimus
significantly improved overall survival (7.3 months vs.
10.9 months, p = 0.008) and reduced the risk of death by
27%. Combination therapy did not improve survival
compared with IFN alone. Based on the results of this
study, temsirolimus was approved for use in metastatic
RCC in the United States and Europe in 2007 [16]. A sub-
set analysis of the phase III trial showed that the benefit of
temsirolimus may be primarily in the poor-risk, non-
clear-cell RCC population. The common adverse events
observed with temsirolimus were asthenia, stomatitis,
rash, nausea, anorexia, and dyspnea. The common abnor-
mal laboratory findings in this trial were hyperglycemia,
hypercholesterolemia, and anemia. The most common
grade 3/4 adverse events observed with temsirolimus
(regardless of causality) in this trial included anemia
(20%), hyperglycemia (11%), asthenia (11%), and dysp-
nea (9%). Most adverse events were manageable with sup-
portive care or dose reduction [34]. An ongoing phase III
trial is evaluating temsirolimus plus bevacizumab vs. IFN-
α plus bevacizumab in patients with advanced clear cell
RCC [35].
Everolimus
Phase II investigation of daily everolimus in 41 patients
with metastatic RCC (of whom 83% had received prior
systemic therapy) showed encouraging activity, with a
median progression-free survival (PFS) of 11.2 months, a
median overall survival of 22.1 months, and a response
rate of 14%; furthermore, more than 70% of patients had
a response or stable disease (SD) lasting for ≥6 months
[36]. Currently, sorafenib and sunitinib are among the
recommended first-line treatment agents for metastatic
RCC [37]. When these VEGFR-targeted therapies are
exhausted, until recently there was no evidence that dem-
onstrated clearly which therapy should be offered next. To
address this unmet need, a phase III double-blind, rand-
omized, placebo-controlled trial (RECORD-1) was initi-
ated to evaluate the activity of daily oral everolimus in
patients whose disease had progressed following therapy
with VEGFR tyrosine kinase inhibitors (TKIs) [38]. Eligi-
bility criteria included disease progression during or
within 6 months of treatment with sunitinib and/or soraf-
enib. Previous treatment with cytokines or bevacizumab
was permitted. A total of 416 patients from 86 centers
were enrolled and stratified by the number of previous
treatments (sorafenib or sunitinib [1 TKI] vs. sorafenib as
well as sunitinib [2 TKIs]) and MSKCC prognostic risk
group (favorable, intermediate, or poor). Patients were
then randomized 2:1 to treatment with everolimus (10
mg daily) and best supportive care (BSC) or to placebo
and BSC. Treatment was continued until disease progres-
sion, unacceptable toxicity, death, or discontinuation for
other reasons. Patients randomized to placebo and BSC
were allowed to cross over to everolimus at disease pro-
gression. At baseline, the majority of patients were in the
intermediate MSKCC risk group (56% and 57% in
everolimus and placebo groups, respectively), and most
had received only 1 prior TKI (74% in both groups). After
the second interim analysis, the study was terminated
early after 191 progression events were observed because
the prespecified efficacy endpoint was met [38]. Based on
analyses from the end of the double-blind period,
everolimus significantly improved PFS vs. placebo: 4.9
months vs. 1.9 months, respectively (hazard ratio: 0.33;
Chemical structures of ridaforolimus, everolimus, and tem- sirolimus Figure 2
Chemical structures of ridaforolimus, everolimus, 
and temsirolimus.
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95% confidence interval [CI]: 0.25-0.43; p < 0.001) [39].
Everolimus significantly increased median PFS in each
MSKCC risk group and regardless of whether patients had
received 1 or 2 prior TKIs. Similar to another mTOR inhib-
itor, temsirolimus, the most common adverse events of all
grades observed in everolimus-treated patients included
fatigue, stomatitis, rash, nausea, anorexia, and stomatitis.
The classic mTOR inhibitor-related abnormal laboratory
findings, including anemia, hypercholesterolemia, hyper-
triglyceridemia, and hyperglycemia were observed [38].
The most common treatment-related grade 3/4 adverse
events with everolimus were lymphopenia (15%), hyper-
glycemia (12%), and anemia (9%). Most adverse events
were manageable with supportive care or dose reduction.
Noninfectious pneumonitis associated with rapamycin or
rapamycin derivative treatment was previously reported
[31] and also was seen with everolimus in this trial.
Approximately 14% of patients receiving everolimus
developed noninfectious pneumonitis; however, only 3%
of patients had grade 3 severity and no patients had grade
4 severity. Most cases of noninfectious pneumonitis were
mild (grade 1/2) and medically manageable [39].
Based on these clinical trial data, algorithms that define
evidence-based treatment options for metastatic RCC
have been developed to include mTOR inhibitors, includ-
ing temsirolimus for the treatment of patients with meta-
static RCC with selected risk features and everolimus for
the treatment of metastatic RRC in patients whose disease
recurred following prior TKI therapy [40,41].
Ongoing Trials in RCC
Further development of mTOR inhibitors for the treat-
ment of RCC is ongoing in combination with antiang-
iogenic agents such as bevacizumab, sorafenib, and
sunitinib. The combination of everolimus and bevacizu-
mab is active and well tolerated in patients with metastatic
clear cell RCC; cohorts of first-line and previously treated
patients were examined in the study [42]. A randomized
trial (RECORD-2) is ongoing to evaluate everolimus plus
bevacizumab vs. interferon-α plus bevacizumab in
patients with progressive, metastatic clear cell RCC [43]. A
planned randomized trial (RECORD-3) will compare
first-line everolimus followed by second-line sunitinib vs.
the alternate sequence in patients with metastatic RCC
[44].
Future Directions With mTOR Inhibitors
The results of preclinical and phase I studies, as well as
data from biomarker studies showing oncogenic transfor-
mation in mTOR-linked pathways (Table 1) suggest that
mTOR inhibitors may have anticancer activity in many
tumor types. In addition to RCC, pivotal clinical trials
with mTOR inhibitors are ongoing in many cancers,
including but not limited to: neuroendocrine tumors
(NET), pancreatic islet cell tumors, breast cancer, diffuse
large B-cell lymphoma, hepatocellular carcinoma, and
gastric cancer. Phase II studies have also been performed
in pancreatic adenocarcinoma, sarcoma, endometrial can-
cer, and non-small cell lung cancer (NSCLC).
Neuroendocrine Tumors
Neuroendocrine tumors are characterized by their ability
to manufacture and secrete peptides that cause hormonal
syndromes [45]. Although these tumor types are rare,
their incidence appears to be increasing. Metastatic low-
grade NETs are generally resistant to chemotherapy and
Table 3: mTOR Inhibitors: Phase I and Pharmacokinetic Data
mTOR Inhibitor T1/2 (h) Primary 
Metabolite
Dose and Schedule MTD DLTs (all grade 3) Suggested Phase II 
Dose
Ridaforolimus [22] 56-74 Not sirolimus 
pro-drug
3-28 mg/d IV × 5 d q 2 wk 18.75 mg Mouth sores 12.5 mg IV × 5 d q 2 wk
Everolimus [25,29] ~30 Not sirolimus 
pro-drug
Oral daily: 5-10 mg/d
Oral weekly: 5-70 mg/wk
NR Daily: hyperglycemia, 
stomatitis
Weekly: stomatitis, 
fatigue, neutropenia, 
hyperglycemia
Daily: 10 mg
Weekly: 50-70 mg
Temsirolimus [26] 13-22 Sirolimus 7.5-220 mg/m2/wk Formal definition 
of MTD not met
Neutropenia, 
thrombocytopenia, 
hypophosphatemia; 
asthenia, diarrhea; manic-
depressive syndrome, 
stomatitis; ALT elevation
25, 75, and 250 mg 
(flat dose) wkly
*In heavily pretreated patients.
†In minimally pretreated patients, no MTD was established, but the maximum acceptable dose was 19 mg/m2 due to grade 3 stomatitis and dose 
reductions in 2 patients.
NR = Not reached.Journal of Hematology & Oncology 2009, 2:45 http://www.jhoonline.org/content/2/1/45
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are relatively incurable, though hormonal symptoms are
managed with somatostatin analogues [46,47].
Temsirolimus and everolimus have both been studied in
patients with advanced NET. Weekly infusions of tem-
sirolimus demonstrated modest activity in patients (n =
37) with progressive NET in a phase II study, with an over-
all response rate (ORR) of 5.6% [30]. In another phase II
study, daily administration of everolimus in combination
with monthly intravenous octreotide (a somatostatin ana-
logue) for up to 12 months provided more notable results
in one cohort of patients (n = 30) with carcinoid or islet
cell tumors, with an ORR of 20%, a median PFS duration
of 60 weeks, and acceptable tolerability [48].
The RADIANT-1 phase II trial evaluated everolimus in
patients with metastatic pancreatic NETs whose disease
progressed on prior cytotoxic chemotherapy [49]. Patients
were enrolled into 2 strata based on whether they were
previously receiving octreotide LAR therapy; patients in
stratum 1 received oral everolimus 10 mg/day alone (n =
115) and patients in stratum 2 received oral everolimus
10 mg/day plus octreotide LAR intramuscularly every 28
days at their current dose (n = 45). Most patients had been
diagnosed > 2 years before study entry, and over 90% of
patients in both strata had liver metastases. The ORR (by
central radiology) was 9.6% in stratum 1 and 4.4% in stra-
tum 2. Stable disease was maintained in 68% of patients
in stratum 1 and 80% of patients in stratum 2. Median PFS
(by central radiology) was 9.7 months in stratum 1 and
16.7 months in stratum 2, and median overall survival
was 24.9 months in stratum 1 and not reached in stratum
2. Treatment was generally well tolerated in both strata.
Based on these encouraging results, 2 subsequent RADI-
ANT studies are ongoing. RADIANT-2 is a randomized,
double-blind, placebo-controlled, multicenter phase III
study of octreotide LAR with everolimus or placebo in
patients with advanced carcinoid tumors [50]. The RADI-
ANT-2 study has completed accrual. RADIANT-3, a rand-
omized, double-blind phase III trial, has completed
enrollment and is currently ongoing to further evaluate
everolimus in the treatment of patients with pancreatic
NET [51].
Breast Cancer
In breast cancer, resistance to treatment with endocrine
therapies and HER-2 targeted agents inevitably develops
in many patients [52,53]. mTOR inhibitors have shown
clinical activity in patients with advanced breast cancer
[54,55] and are being actively investigated in this setting
in combination with other agents that have shown clinical
activity in metastatic breast cancer (MBC).
A phase III study of temsirolimus in combination with
letrozole did not demonstrate benefit over letrozole alone
in patients with MBC and was terminated at an interim
analysis [56]. These results may reflect the need for better
biomarker-based patient selection.
A study evaluating 2 schedules of oral everolimus admin-
istration (continuous daily vs. weekly) in patients with
MBC showed that continuous daily administration pro-
duced greater tumor shrinkage [55]. In 2006, a phase III
trial evaluating temsirolimus in combination with endo-
crine therapy (letrozole) in estrogen receptor-positive
(ER+) women with advanced breast cancer was discontin-
ued due to missed endpoints involving efficacy [56,57].
The development of mTOR inhibitors in MBC continued,
and investigators approached a phase II everolimus neo-
adjuvant trial by first attempting to identify biomarkers to
predict which patients might be more likely to respond to
a combination including an mTOR inhibitor and endo-
crine therapy. In this study, the response rate by clinical
palpation in patients treated with everolimus and letro-
zole was superior to that in patients treated with letrozole
alone [58]. Inhibition of tumor proliferation, as reflected
by decreased Ki67-positive tumor cells, was more promi-
nent with everolimus plus letrozole compared with letro-
zole alone (mean reduction at day 15 relative to baseline
90.7% in everolimus group vs. 74.8% in placebo group; p
= 0.0002), and inhibition of mTOR activity (decreased
pS6K levels) was observed in patients treated with the
combination [58]. Results of a phase I trial of this combi-
nation in patients with MBC whose disease was stable or
had progressed after 4 months with letrozole alone
showed that it was well tolerated and active in this patient
population [59]. An ongoing randomized, double-blind,
placebo-controlled phase III trial (BOLERO-2) is evaluat-
ing everolimus in combination with exemestane in
patients with estrogen-receptor positive locally advanced
or metastatic breast cancer who are refractory to letrozole
or anastrozole [60].
Ongoing phase I studies are evaluating the addition of
everolimus to cytotoxic chemotherapy and HER2-targeted
therapy in hopes that these combinations can delay or
overcome trastuzumab resistance in HER2-positive breast
cancer [61,62]. Either daily or weekly everolimus was
administered in combination with weekly chemotherapy
and trastuzumab. Preliminary results have been encourag-
ing: an unexpected degree of anticancer activity has been
seen in patients resistant to both taxanes and trastuzu-
mab, and the combinations with everolimus were well
tolerated. A randomized, double-blind, placebo-control-
led phase III trial (BOLERO-1) is planned to evaluate the
addition of everolimus to paclitaxel and trastuzumab as
first-line therapy in patients with HER2-positive locally
advanced or metastatic breast cancer [63].
Lymphoma
Lymphomas appear to be sensitive to mTOR inhibitor
therapy. Everolimus (10 mg/day PO, 28-day/cycle untilJournal of Hematology & Oncology 2009, 2:45 http://www.jhoonline.org/content/2/1/45
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progression or toxicity) was evaluated in 145 previously
treated patients with aggressive lymphomas or uncom-
mon lymphomas, including 77 with aggressive NHL, 41
with indolent NHL, 8 with T-cell NHL, and 17 with Hodg-
kin disease [64]. Patients had received a median of 4 prior
therapies. The ORR was 33% (48/145), with 5 patients
achieving CR and 43 patients achieving PR. The median
time to progression in all patients was 4.3 months.
Everolimus was generally well tolerated, and grade 3/4
adverse events included anemia (16%), neutropenia
(17%), thrombocytopenia (35%), hypercholesterolemia
(1%), hyperglycemia (5%), and hypertriglyceridemia (n =
1). In the 17 patients with Hodgkin lymphoma, 15
patients were evaluable for response; 7 (47%) had PRs
[65]. An open-label phase II trial (PILLAR-1) is ongoing to
evaluate everolimus in previously treated patients with
mantle cell lymphoma (MCL) who are refractory or intol-
erant to bortezomib therapy [66]. An ongoing rand-
omized, double-blind, multicenter phase III study
(PILLAR-2) is evaluating everolimus as adjuvant therapy
in poor-risk patients with diffuse large B cell lymphoma
who achieved complete remission with first-line rituxi-
mab and chemotherapy [67].
Temsirolimus, administered intravenously at 25 mg
weekly, also has shown activity in NHL subtypes.
Response rates of 36% (DLCL) and 56% (follicular lym-
phoma) were observed in a 56-patient study [68]. In
relapsed MCL, 1 CR and several PRs were observed in a
phase II temsirolimus study [69]. Positive results were
also recently reported from a large open-label phase III
study, which compared temsirolimus, 175 mg three times
a week followed by either 75 mg or 25 mg weekly, with
investigator's choice of therapy in 162 patients with
relapsed or refractory MCL [70]. The ORR was signifi-
cantly higher in the temsirolimus 175 mg/75 mg dose
group (22%) vs. investigator's choice (2%; p = 0.0019).
Median PFS was 4.8 months with temsirolimus 175 mg/
75 mg vs. 3.4 months with temsirolimus 175 mg/25 mg
and 1.9 months with investigator's choice of therapy (p =
0.0009 for temsirolimus 175 mg/75 mg vs. investigator's
choice). No significant differences in OS were observed
(12.8 months vs. 10.0 months vs. 9.7 months with tem-
sirolimus 175 mg/75 mg, temsirolimus 175 mg/25 mg,
and investigator's choice, respectively). The most com-
mon grade 3/4 adverse events observed in the 2 tem-
sirolimus treatment groups were thrombocytopenia
(52%-59%), anemia (11%-20%), asthenia (13%-19%),
and diarrhea (7%-11%). Recently, the EMEA Committee
for Medicinal Products for Human Use rendered a posi-
tive opinion for temsirolimus to be approved in Europe to
treat patients with relapsed/refractory MCL [71].
Ridaforolimus was evaluated in a phase II trial of 52 heav-
ily pretreated patients with a variety of hematologic malig-
nancies, including acute myelogenous leukemia (AML),
chronic myelogenous leukemia (CML), myelodysplastic
syndrome (MDS), acute lymphocytic leukemia (ALL),
chronic lymphocytic leukemia (CLL), agnogenic myeloid
metaplasia (AMM), and MCL. The PR rate was 10% (2 of
7 patients with AMM and 3 of 9 patients with MCL), and
SD/hematologic improvement occurred in 40% (4 of 22
patients with AML, 1 of 2 patients with MDS, 3 of 7
patients with AMM, 6 of 8 patients with CLL, 2 of 2
patients with T-cell lymphoma, and 4 of 9 patients with
MCL). Ridaforolimus was well tolerated [72].
Overall, these encouraging results provide support for
conducting additional clinical trials with mTOR inhibi-
tors in both NHL and Hodgkin lymphoma.
Gastric Cancer
Everolimus was evaluated in a multicenter phase II study
involving previously treated patients with metastatic gas-
tric cancer [73]. In an analysis of trial data after 54 patients
were enrolled, the disease control rate (proportion of
patients with CR, PR, or SD as the best overall response at
the objective tumor assessment performed according to
RECIST) was 55%, median PFS was 2.7 months, and tol-
erability was acceptable [74]. These findings support the
further evaluation of everolimus in patients with
advanced gastric cancer. A randomized, double-blind,
multicenter phase III study (GRANITE-1) is planned to
compared everolimus plus BSC vs. placebo plus BSC in
patients with advanced gastric cancer who progressed after
1 or 2 prior chemotherapy regimens [75].
Sarcoma
Of the mTOR inhibitors, ridaforolimus has been most
thoroughly investigated in sarcoma. A phase II trial of
temsirolimus in 41 patients failed to meet endpoints in
soft tissue sarcomas [76]. In contrast, a clinical benefit
response (CBR = CR + PR + SD) rate of 29% was reported
in a trial of 212 patients with advanced bone and soft tis-
sue sarcomas treated with ridaforolimus. The subset of
patients who achieved a CBR had a longer median overall
survival than the entire study population [77]. Results of
a recent study of specimens from patients with high-grade
sarcomas suggested that the level of expression of phos-
phorylated S6 was predictive of tumor response to rida-
forolimus [78]. An oral formulation of ridaforolimus will
be studied as maintenance therapy in a phase III trial, the
Sarcoma Multi-Center Clinical Evaluation of the Efficacy
of Ridaforolimus (SUCCEED) trial, which is currently
enrolling patients with metastatic soft-tissue or bone sar-
comas [79].
Endometrial Cancer
Clinical trials with each of the mTOR inhibitors have been
conducted in endometrial cancer, and preliminary results
suggest activity. Oza et al. reported an ORR of 26% tem-
sirolimus in previously untreated patients with metastaticJournal of Hematology & Oncology 2009, 2:45 http://www.jhoonline.org/content/2/1/45
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or recurrent (after hormonal therapy) endometrial cancer
[80]. Trials with ridaforolimus and everolimus have been
conducted in previously treated patients, and both mTOR
inhibitors appear to have activity in this setting. A CBR of
33%, with 2 partial responses, was observed in patients
who received ridaforolimus [81]. Similar results were
observed in patients treated with daily everolimus; CBR
was observed in 43% of evaluable patients [82].
Non-Small Cell Lung Cancer
Everolimus monotherapy was evaluated in a phase II trial
involving patients with stage IIIB/IV NSCLC who had pre-
viously received = 2 prior chemotherapy regimens [83].
Patients were enrolled into 2 strata; stratum 1: prior plati-
num-based chemotherapy (n = 42) and stratum 2: prior
chemotherapy plus prior TKI therapy (n = 43). The ORR
was 4.7% (7.1% in stratum 1 and 2.3% in stratum 2), with
an overall disease control rate of 47.1%. Median PFS was
2.6 months in stratum 1 and 2.7 months in stratum 2.
These results prompted further investigation of
everolimus in NSCLC.
The combination of everolimus with the EGFR tyrosine
kinase inhibitor gefitinib was evaluated in a phase I trial
of 10 patients with progressive NSCLC, based on the
hypothesis that inhibition of the PI3K/Akt/mTOR path-
way by both agents would result in additive or synergistic
activity. Daily doses of everolimus 5 mg and 10 mg were
assessed; the 10-mg dose was discontinued due to dose-
limiting toxicities of grade 5 hypotension and grade 3 sto-
matitis. However, partial radiographic responses were
found in 2 patients who received the 5-mg dose, which
was tolerable in combination with gefitinib [84]. These
results prompted further study of everolimus/gefitinib in
a phase II trial that enrolled patients with stage IIIB/IV
NSCLC who were smokers in to 2 cohorts: cohort 1
included previously untreated patients and cohort 2
included patients who had received prior platinum/
docetaxel therapy [85]. In a report of results from 25
patients (11 in cohort 1 and 14 in cohort 2) a PR rate of
17% was observed.
A number of phase I and II trials evaluating everolimus in
combination with TKIs and other agents are ongoing,
including a phase II trial of the combination of
everolimus and the EGFR tyrosine kinase inhibitor erlo-
tinib in pretreated patients with advanced NSCLC [86]
and a phase I/II trial evaluating everolimus plus carbopla-
tin/paclitaxel and bevacizumab as first line therapy in
stage IIIB/IV NSCLC [87].
Conclusion
The improved understanding of molecular biology per-
mits the development of agents that target dysregulated
pathways in cancer cells. mTOR is a central regulator of
cell growth, cell proliferation, and angiogenesis. Because
mTOR is activated through cellular pathways that are dys-
regulated in many different types of cancer, single-agent
use of mTOR inhibitors could potentially result in anti-
cancer activity in numerous tumor types. Additionally,
because mTOR is pivotal in the cellular processes that
tumor cells depend on for cellular metabolism, prolifera-
tion, survival and progression, combining an mTOR
inhibitor with other anticancer agents could serve to sen-
sitize tumor cells to these agents. The potential exists for
these combinations to produce additional activity or per-
haps delay or prevent the development of resistance to
these agents. The results of ongoing clinical trials with
mTOR inhibitors, as single agents and in combination,
will better define their activity in cancer.
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